Monotherapy with antiangiogenic drugs produces marginal clinical benefits in patients with cancer; however, combination with chemotherapy can produce a synergistic antitumor effect.[22, 39, 44] Thus, glucagon could be considered as an antiangiogenic agent for combination therapy, which significantly inhibited tumor growth in our models. This evidence concerns the gene GCG and cancer.